Quantifying Adaptive and Innate Immune Responses in HIV-Infected Participants Using a Novel High Throughput Assay.
HIV infection is characterised by persistent immune dysfunction of both the adaptive and innate immune responses. The aim of this study was to evaluate these responses using a novel high throughput assay in healthy controls and HIV-infected individuals prior to and following anti-retroviral treatmen...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2016-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5147821?pdf=render |
id |
doaj-9864686ba9ad4b0e9a2cf3521c876c27 |
---|---|
record_format |
Article |
spelling |
doaj-9864686ba9ad4b0e9a2cf3521c876c272020-11-24T22:14:35ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-011112e016654910.1371/journal.pone.0166549Quantifying Adaptive and Innate Immune Responses in HIV-Infected Participants Using a Novel High Throughput Assay.Michelle K YongPaul U CameronTim SpelmanJulian H ElliottChristopher K FairleyJeffrey BoyleMisato MiyamasuSharon R LewinHIV infection is characterised by persistent immune dysfunction of both the adaptive and innate immune responses. The aim of this study was to evaluate these responses using a novel high throughput assay in healthy controls and HIV-infected individuals prior to and following anti-retroviral treatment (ART).Cross-sectional study.Whole blood was assessed using the QuantiFERON Monitor® (QFM) assay containing adaptive and innate immunostimulants. Interferon (IFN)-γ levels (IU/mL) were measured by enzyme-linked immunosorbent assay (ELISA).We recruited HIV-infected participants (n = 20 off ART and viremic; n = 59 on suppressive ART) and HIV-uninfected controls (n = 229). Median IFN-γ production was significantly higher in HIV-infected participants compared to controls (IFN-γ 512 vs 223 IU/ml, p<0.0001), but within the HIV-infected participants there was no difference between those on or off ART (median IFN-γ 512 vs 593 IU/ml p = 0.94). Amongst the HIV-infected participants, IFN-γ production was higher in individuals with CD4 count>350 compared to <350 cells/μL (IFN-γ IU/ml 561 vs 259 p = 0.02) and in males compared to females (IFN-γ 542 vs 77 IU/ml p = 0.04). There were no associations between IFN-γ production and age, plasma HIV RNA, nadir CD4 count or duration of HIV infection. Using a multivariable analysis, neither CD4 nor sex were independently predictive of IFN-γ production.Using a high throughput assay which assesses both adaptive and innate immune function, we showed elevated IFN-γ production in HIV-infected patients both on and off ART. Further research is warranted to determine if changes in QuantiFERON Monitor® are associated with clinical outcomes.http://europepmc.org/articles/PMC5147821?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Michelle K Yong Paul U Cameron Tim Spelman Julian H Elliott Christopher K Fairley Jeffrey Boyle Misato Miyamasu Sharon R Lewin |
spellingShingle |
Michelle K Yong Paul U Cameron Tim Spelman Julian H Elliott Christopher K Fairley Jeffrey Boyle Misato Miyamasu Sharon R Lewin Quantifying Adaptive and Innate Immune Responses in HIV-Infected Participants Using a Novel High Throughput Assay. PLoS ONE |
author_facet |
Michelle K Yong Paul U Cameron Tim Spelman Julian H Elliott Christopher K Fairley Jeffrey Boyle Misato Miyamasu Sharon R Lewin |
author_sort |
Michelle K Yong |
title |
Quantifying Adaptive and Innate Immune Responses in HIV-Infected Participants Using a Novel High Throughput Assay. |
title_short |
Quantifying Adaptive and Innate Immune Responses in HIV-Infected Participants Using a Novel High Throughput Assay. |
title_full |
Quantifying Adaptive and Innate Immune Responses in HIV-Infected Participants Using a Novel High Throughput Assay. |
title_fullStr |
Quantifying Adaptive and Innate Immune Responses in HIV-Infected Participants Using a Novel High Throughput Assay. |
title_full_unstemmed |
Quantifying Adaptive and Innate Immune Responses in HIV-Infected Participants Using a Novel High Throughput Assay. |
title_sort |
quantifying adaptive and innate immune responses in hiv-infected participants using a novel high throughput assay. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2016-01-01 |
description |
HIV infection is characterised by persistent immune dysfunction of both the adaptive and innate immune responses. The aim of this study was to evaluate these responses using a novel high throughput assay in healthy controls and HIV-infected individuals prior to and following anti-retroviral treatment (ART).Cross-sectional study.Whole blood was assessed using the QuantiFERON Monitor® (QFM) assay containing adaptive and innate immunostimulants. Interferon (IFN)-γ levels (IU/mL) were measured by enzyme-linked immunosorbent assay (ELISA).We recruited HIV-infected participants (n = 20 off ART and viremic; n = 59 on suppressive ART) and HIV-uninfected controls (n = 229). Median IFN-γ production was significantly higher in HIV-infected participants compared to controls (IFN-γ 512 vs 223 IU/ml, p<0.0001), but within the HIV-infected participants there was no difference between those on or off ART (median IFN-γ 512 vs 593 IU/ml p = 0.94). Amongst the HIV-infected participants, IFN-γ production was higher in individuals with CD4 count>350 compared to <350 cells/μL (IFN-γ IU/ml 561 vs 259 p = 0.02) and in males compared to females (IFN-γ 542 vs 77 IU/ml p = 0.04). There were no associations between IFN-γ production and age, plasma HIV RNA, nadir CD4 count or duration of HIV infection. Using a multivariable analysis, neither CD4 nor sex were independently predictive of IFN-γ production.Using a high throughput assay which assesses both adaptive and innate immune function, we showed elevated IFN-γ production in HIV-infected patients both on and off ART. Further research is warranted to determine if changes in QuantiFERON Monitor® are associated with clinical outcomes. |
url |
http://europepmc.org/articles/PMC5147821?pdf=render |
work_keys_str_mv |
AT michellekyong quantifyingadaptiveandinnateimmuneresponsesinhivinfectedparticipantsusinganovelhighthroughputassay AT paulucameron quantifyingadaptiveandinnateimmuneresponsesinhivinfectedparticipantsusinganovelhighthroughputassay AT timspelman quantifyingadaptiveandinnateimmuneresponsesinhivinfectedparticipantsusinganovelhighthroughputassay AT julianhelliott quantifyingadaptiveandinnateimmuneresponsesinhivinfectedparticipantsusinganovelhighthroughputassay AT christopherkfairley quantifyingadaptiveandinnateimmuneresponsesinhivinfectedparticipantsusinganovelhighthroughputassay AT jeffreyboyle quantifyingadaptiveandinnateimmuneresponsesinhivinfectedparticipantsusinganovelhighthroughputassay AT misatomiyamasu quantifyingadaptiveandinnateimmuneresponsesinhivinfectedparticipantsusinganovelhighthroughputassay AT sharonrlewin quantifyingadaptiveandinnateimmuneresponsesinhivinfectedparticipantsusinganovelhighthroughputassay |
_version_ |
1725798207546458112 |